To understand pharmacotherapy for NASH, mice with established NASH hepatic lesions were treated with either FXR agonist obeticholic acid (Ocaliva), or CCR2/5 antagonist Cenicriviroc. This evidence concerns the gene NR1H4 and metabolic dysfunction-associated steatohepatitis.